Bal Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2025, 1. Approved the audited financial results ( stand alone and consolidated )of the Company for the financial year ended 31.03.20252.Recommended Final Dividend of Re.1.2 per equity share of Rs.10 each , subject to the approval of members at the ensuing AGM
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Bal Pharma Limited, at its meeting held on May 29, 2025, approved the audited financial results (both standalone and consolidated) for the financial year ended March 31, 2025. The Board also recommended a final dividend of Re.1.2 per equity share on shares of face value Rs.10 each, which translates to a 12% dividend on face value. The dividend is subject to approval by shareholders at the upcoming Annual General Meeting (AGM). No other operational details or financial figures have been disclosed in this filing.
The dividend recommendation signals that the company is in a position to reward shareholders and likely reported profitable operations for FY25. The approval of audited results paves the way for the AGM, after which shareholders can expect the final dividend to be credited, subject to the record date announced later.